Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ELANE | P08246 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608300 | 0.85 | HTT (0.42) | POLBELANEALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5608890 | 0.85 | KMT2A (0.42) | POLBELANEALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5608981 | 0.84 | POLB (0.46) | POLBALDH1A1RAB9ASMN1; SMN2HTT | |
| SCHEMBL5608927 | 0.84 | LMNA (0.47) | POLBALDH1A1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL5608332 | 0.80 | POLB (0.50) | POLBALDH1A1SMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5608628 | 0.80 | MEN1 (0.43) | POLBALDH1A1RAB9AKMT2ANPC1 | |
| SCHEMBL26545208 | 0.76 | ELANE (0.63) | POLBELANEALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL5195766 | 0.76 | EPHX1 (0.50) | POLBELANERAB9AHTTKMT2A | |
| SCHEMBL10911289 | 0.75 | POLB (0.76) | POLBELANEALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL10782887 | 0.75 | POLB (0.76) | POLBELANEALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | POLB 1436/4885ELANE 819/4885ALDH1A1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.